Table 1

Baseline characteristics of patients with type 2 diabetes in a randomized, double-blind, placebo-controlled trial of NGM282

Placebo 
(n = 20)NGM282 2 mg
(n = 21)NGM282 5 mg 
(n = 20)NGM282 10 mg 
(n = 20)
Age (years)57.3 ± 9.459.5 ± 6.955.9 ± 9.061.1 ± 8.4
Sex
 Male15 (75)15 (71)12 (60)16 (80)
 Female5 (25)6 (29)8 (40)4 (20)
Race
 Asian01 (5)1 (5)0
 Black0000
 White14 (70)17 (81)17 (85)15 (75)
 Pacific Islander0001 (5)
 Other6 (30)3 (14)2 (10)4 (20)
Metabolic factors
 Glucose (mg/dL)169.2 ± 48.6163.8 ± 27.0158.4 ± 23.4153.0 ± 34.2
 HbA1c (%)7.7 ± 0.77.5 ± 0.77.2 ± 0.47.2 ± 0.6
 HbA1c (mmol/mol)83.9 ± 7.681.8 ± 7.678.5 ± 4.478.5 ± 6.5
 Fructosamine (μmol/L)288.4 ± 47.8277.2 ± 40.0266.8 ± 35.9269.7 ± 32.8
 GTT glucose AUC16.0 ± 3.215.9 ± 2.415.6 ± 2.215.5 ± 2.3
 GTT insulin AUC39.5 ± 30.737.9 ± 6.253.9 ± 29.350.2 ± 30.5
 Insulin (μIU/mL)13.9 ± 8.215.4 ± 6.018.9 ± 7.517.0 ± 9.2
 HOMA-IR4.8 ± 3.16.2 ± 2.57.5 ± 3.96.8 ± 5.0
 HOMA-bcf58.1 ± 58.056.5 ± 26.567.4 ± 26.475.4 ± 67.4
 Weight (kg)97.6 ± 18.695.3 ± 15.595.5 ± 14.795.7 ± 16.0
 BMI (kg/m2)32.4 ± 4.832.0 ± 4.532.2 ± 3.532.1 ± 4.6
Liver enzymes (units/L)
 ALP75.0 ± 34.365.3 ± 23.465.7 ± 16.677.9 ± 30.6
 ALT33.9 ± 16.727.6 ± 10.636.7 ± 25.934.4 ± 19.8
 AST25.1 ± 11.421.5 ± 7.627.4 ± 14.926.4 ± 11.5
 GGT60.6 ± 104.932.5 ± 17.335.4 ± 13.953.0 ± 36.6
  • Data are n (%) or mean ± SD. AUC, area under curve; GGT, γ-glutamyl transpeptidase.